Co-Diagnostics, Inc. (MUN:C970)

Co-Diagnostics Statistics

Total Valuation

Co-Diagnostics has a market cap or net worth of EUR 4.06 million. The enterprise value is -4.33 million.

Market Cap	4.06M
Enterprise Value	-4.33M

Important Dates

The next estimated earnings date is Thursday, March 19, 2026.

Earnings Date	Mar 19, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	2.03M
Shares Outstanding	n/a
Shares Change (YoY)	+11.72%
Shares Change (QoQ)	+14.45%
Owned by Insiders (%)	5.08%
Owned by Institutions (%)	12.20%
Float	1.80M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	9.39
PB Ratio	0.12
P/TBV Ratio	0.35
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	0.16
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	0.16

Financial Position

The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.04.

Current Ratio	3.81
Quick Ratio	3.36
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	-0.05
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -62.12% and return on invested capital (ROIC) is -119.76%.

Return on Equity (ROE)	-62.12%
Return on Assets (ROA)	-37.92%
Return on Invested Capital (ROIC)	-119.76%
Return on Capital Employed (ROCE)	-86.56%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	3,279
Profits Per Employee	-207,789
Employee Count	132
Asset Turnover	0.01
Inventory Turnover	0.28

Taxes

Income Tax	-980,517
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	n/a
Average Volume (20 Days)	165

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	0.80

Income Statement

In the last 12 months, Co-Diagnostics had revenue of EUR 432,876 and -27.43 million in losses. Loss per share was -24.72.

Revenue	432,876
Gross Profit	147,314
Operating Income	-30.28M
Pretax Income	-28.41M
Net Income	-27.43M
EBITDA	-29.26M
EBIT	-30.28M
Loss Per Share	-24.72

Balance Sheet

The company has 9.75 million in cash and 1.25 million in debt, with a net cash position of 8.50 million.

Cash & Cash Equivalents	9.75M
Total Debt	1.25M
Net Cash	8.50M
Net Cash Per Share	n/a
Equity (Book Value)	33.95M
Book Value Per Share	21.15
Working Capital	8.83M

Cash Flow

In the last 12 months, operating cash flow was -26.57 million and capital expenditures -546,380, giving a free cash flow of -27.11 million.

Operating Cash Flow	-26.57M
Capital Expenditures	-546,380
Free Cash Flow	-27.11M
FCF Per Share	n/a

Margins

Gross Margin	34.03%
Operating Margin	-6,995.70%
Pretax Margin	-6,562.79%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Co-Diagnostics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.72%
Shareholder Yield	-11.72%
Earnings Yield	-675.01%
FCF Yield	-667.22%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Co-Diagnostics has an Altman Z-Score of -1.69 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.69
Piotroski F-Score	1